Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ARUK2010694
- Development stage
- Unknown
- Lead developer
- University of Cambridge
01
Overview
ARUK2010694: sourced facts only. name: "Herein, we describe the optimization of the CDK2 inhibitor NU6140 to the potent and selective NUAK1 inhibitor ARUK2010694, with a significantly improved mouse plasma half-life." [PMID:41257021]; target: "Herein, we describe the optimization of the CDK2 inhibitor NU6140 to the potent and selective NUAK1 inhibitor ARUK2010694, with a significantly improved mouse plasma half-life." [PMID:41257021]; developer: "The ALBORADA Drug Discovery Institute, University of Cambridge, Island Research Building, Cambridge Biomedical Campus, Hills Road, Cambridge CB2 0AH, United Kingdom." [PMID:41257021]
02
Targets
NUAK1 (NUAK family SNF1-like kinase 1)
Beyond the preview
Go deeper on ARUK2010694.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ARUK2010694.